DHAX-R regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[dexamethasone]], High dose [[cytarabine|cytarabine (Ara-C)]], [[oxaliplatin]] ,[[rituximab]], used to treat relapsed/refractory [[non-Hodgkin lymphoma|B-cell non-Hodgkin lymphoma]] | {{PAGENAME}} refers to a regimen consisting of [[dexamethasone]], High dose [[cytarabine|cytarabine (Ara-C)]], [[oxaliplatin]] ,[[rituximab]], used to treat relapsed/refractory [[non-Hodgkin lymphoma|B-cell non-Hodgkin lymphoma]]<ref name="pmid20709662">{{cite journal| author=Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J et al.| title=Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. | journal=Clin Lymphoma Myeloma Leuk | year= 2010 | volume= 10 | issue= 4 | pages= 262-9 | pmid=20709662 | doi=10.3816/CLML.2010.n.055 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20709662 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 23: | Line 22: | ||
==Indications== | ==Indications== | ||
*Relapsed/refractory [[non-Hodgkin lymphoma|B-cell non-Hodgkin lymphoma]]<ref name="pmid20709662">{{cite journal|author=Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J et al.| title=Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. | journal=Clin Lymphoma Myeloma Leuk | year= 2010 | volume= 10 | issue= 4 | pages= 262-9 | pmid=20709662 | doi=10.3816/CLML.2010.n.055 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20709662 }} </ref> | *Relapsed/refractory [[non-Hodgkin lymphoma|B-cell non-Hodgkin lymphoma]]<ref name="pmid20709662">{{cite journal| author=Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J et al.| title=Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. | journal=Clin Lymphoma Myeloma Leuk | year= 2010 | volume= 10 | issue= 4 | pages= 262-9 | pmid=20709662 | doi=10.3816/CLML.2010.n.055 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20709662 }} </ref> | ||
Revision as of 19:46, 12 March 2015
|
WikiDoc Resources for DHAX-R regimen |
|
Articles |
|---|
|
Most recent articles on DHAX-R regimen Most cited articles on DHAX-R regimen |
|
Media |
|
Powerpoint slides on DHAX-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DHAX-R regimen at Clinical Trials.gov Trial results on DHAX-R regimen Clinical Trials on DHAX-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DHAX-R regimen NICE Guidance on DHAX-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on DHAX-R regimen Discussion groups on DHAX-R regimen Patient Handouts on DHAX-R regimen Directions to Hospitals Treating DHAX-R regimen Risk calculators and risk factors for DHAX-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DHAX-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R-DHAX; rituximab/dexamethasone/cytarabine/oxaliplatin
Overview
DHAX-R regimen refers to a regimen consisting of dexamethasone, High dose cytarabine (Ara-C), oxaliplatin ,rituximab, used to treat relapsed/refractory B-cell non-Hodgkin lymphoma[1]
Regimen
DDexamethasone
HHigh dose
Acytarabine (Ara-C)
xoxaliplatin
RRituximab
Indications
- Relapsed/refractory B-cell non-Hodgkin lymphoma[1]
- ↑ 1.0 1.1 Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J; et al. (2010). "Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma". Clin Lymphoma Myeloma Leuk. 10 (4): 262–9. doi:10.3816/CLML.2010.n.055. PMID 20709662.